Alternaturals, Inc. Partners with MAS Capital to Officially Launch NASDAQ Uplisting Plan
2025-11-20
Alternaturals, Inc. (OTC: ANAS) ("Alternaturals" or the "Company"), a US OTC-listed company, announced today that it officially signed a financial services agreement with the internationally renowned financial advisory firm MAS Capital (CI) Inc. ("MAS Capital") on November 17, 2025. Under the agreement, MAS Capital will serve as the Company's exclusive financial advisor, providing comprehensive capital market consulting to fully guide the Company in its transition (uplisting) from the OTC market to the NASDAQ main board.
.jpg)
Alternaturals Group President Maolin Zhang (left) and MAS Capital Founder and Chief Capitalist Aaron Tsai (right) signing the financial services agreement on November 17, 2025.
Founded in 1995, Alternaturals, Inc. is headquartered in Reno, Nevada, USA, with its administrative office located in Xinzhuang District, New Taipei City, Taiwan. In recent years, the Group has successfully integrated multiple enterprises through a precise M&A strategy, including Hong Kong UR Development Group, Beijing Zhongnong Yuanfang Technology, Xi'an Lian-er Technology, Xi'an Lian-er Biotechnology, Chongqing Lian-er-mei Biotechnology, and Xi'an Hua-hui Biotechnology. The Company is committed to introducing cutting-edge technologies such as AI (Artificial Intelligence), IoT (Internet of Things), and Big Data into the biotechnology industry, building a highly competitive group-oriented operational system.
The core objective of this IPO plan is to list on NASDAQ. The Company expects to raise US$25 million and aims to complete the listing between the third and fourth quarters of 2026. The goal is to leverage the power of capital markets to accelerate the expansion of AI biotechnology applications and drive innovation and integration within the general health industry chain.
MAS Capital was founded in 1995 by the renowned Chinese-American investment banker Mr. Aaron Tsai. Its international division specializes in assisting Asian enterprises to list in the United States. As a member of the National Investment Banking Association (NIBA), the firm possesses extensive experience in cross-border capital operations and has successfully guided 101 companies to public listing to date.
Through this strategic cooperation, Alternaturals, Inc. will leverage MAS Capital's deep resources and professional planning capabilities in both US and Chinese capital markets to accelerate the uplisting process. This marks not only a key milestone in the Group's global layout but also aims to translate leading AI biotech technologies into substantial commercial value, creating long-term and robust investment returns for shareholders.
Alternaturals Group President Maolin Zhang (left) and MAS Capital Founder and Chief Capitalist Aaron Tsai (right) signing the financial services agreement on November 17, 2025.
Founded in 1995, Alternaturals, Inc. is headquartered in Reno, Nevada, USA, with its administrative office located in Xinzhuang District, New Taipei City, Taiwan. In recent years, the Group has successfully integrated multiple enterprises through a precise M&A strategy, including Hong Kong UR Development Group, Beijing Zhongnong Yuanfang Technology, Xi'an Lian-er Technology, Xi'an Lian-er Biotechnology, Chongqing Lian-er-mei Biotechnology, and Xi'an Hua-hui Biotechnology. The Company is committed to introducing cutting-edge technologies such as AI (Artificial Intelligence), IoT (Internet of Things), and Big Data into the biotechnology industry, building a highly competitive group-oriented operational system.
The core objective of this IPO plan is to list on NASDAQ. The Company expects to raise US$25 million and aims to complete the listing between the third and fourth quarters of 2026. The goal is to leverage the power of capital markets to accelerate the expansion of AI biotechnology applications and drive innovation and integration within the general health industry chain.
MAS Capital was founded in 1995 by the renowned Chinese-American investment banker Mr. Aaron Tsai. Its international division specializes in assisting Asian enterprises to list in the United States. As a member of the National Investment Banking Association (NIBA), the firm possesses extensive experience in cross-border capital operations and has successfully guided 101 companies to public listing to date.
Through this strategic cooperation, Alternaturals, Inc. will leverage MAS Capital's deep resources and professional planning capabilities in both US and Chinese capital markets to accelerate the uplisting process. This marks not only a key milestone in the Group's global layout but also aims to translate leading AI biotech technologies into substantial commercial value, creating long-term and robust investment returns for shareholders.